Chemours (NYSE:CC) Stock Rating Lowered by Mizuho

Chemours (NYSE:CC) was downgraded by Mizuho from a “strong-buy” rating to a “hold” rating in a research report issued on Tuesday, Zacks reports.

Several other brokerages have also weighed in on CC. Zacks Research upgraded Chemours from a “strong sell” rating to a “hold” rating in a report on Thursday, September 10th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $16.00 target price on shares of Chemours in a report on Friday, October 9th. BMO Capital Markets reduced their price objective on Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a research note on Thursday, August 13th. Weiss Ratings lowered Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, August 6th. Finally, UBS Group lowered their target price on Chemours from $18.00 to $16.00 and set a “neutral” rating on the stock in a research note on Monday, October 5th. Three investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $18.09.

Chemours Price Performance

Shares of NYSE:CC opened at $12.81 on Tuesday. Chemours has a 12 month low of $10.44 and a 12 month high of $28.67. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of -6.71 and a beta of 1.41. The stock’s 50 day moving average price is $14.79 and its 200 day moving average price is $18.97. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.66 and a quick ratio of 0.88.

Chemours (NYSE:CC) last issued its quarterly earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.07). Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.65 billion. During the same period in the previous year, the business posted ($2.54) earnings per share. The business’s revenue for the quarter was down 1.5% compared to the same quarter last year. Equities research analysts anticipate that Chemours will post 0.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Chemours news, CEO Denise Dignam acquired 3,378 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were purchased at an average price of $14.95 per share, with a total value of $50,501.10. Following the completion of the transaction, the chief executive officer owned 339,916 shares in the company, valued at $5,081,744.20. The trade was a 1.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Shane Hostetter acquired 3,350 shares of Chemours stock in a transaction that occurred on Thursday, August 6th. The stock was acquired at an average cost of $14.94 per share, with a total value of $50,049.00. Following the purchase, the chief financial officer owned 102,698 shares in the company, valued at $1,534,308.12. The trade was a 3.37% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 8,663 shares of company stock valued at $130,601 in the last three months. Insiders own 0.85% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Chemours in the second quarter worth about $477,769,000. Wolf Hill Capital Management LP bought a new stake in Chemours during the 2nd quarter valued at approximately $59,698,056. Bank of New York Mellon Corp bought a new stake in Chemours during the 2nd quarter valued at approximately $33,353,000. Legal & General Group Plc bought a new stake in Chemours during the 2nd quarter valued at approximately $28,400,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Chemours in the 2nd quarter valued at approximately $18,119,000. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: BMO Capital reaffirmed its Buy rating, indicating that some analysts still see recovery potential in Chemours despite the recent weakness. BMO Capital reaffirms Buy rating
• Neutral Sentiment: Barclays initiated coverage at Equal Weight, while Mizuho maintained a Neutral rating but reduced its price target to $15 from $18. The new target still implies potential upside from recent trading levels, but the cut signals more cautious expectations. Mizuho downgrades Chemours
• Negative Sentiment: RBC Capital downgraded Chemours to Sector Perform from Outperform and cut its price target to $14 from $22, citing persistent TiO₂ weakness, soft chemical demand and potential headwinds in the Thermal & Specialized Solutions segment through year-end. RBC downgrades Chemours
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action filed against Chemours and certain officers. The case covers investors who purchased shares from February 20 through August 4, 2026, and alleges investors were harmed by disclosures concerning Opteon refrigerant aftermarket demand. The lead-plaintiff deadline is December 7, 2026. Although the allegations have not been proven, the litigation creates legal, financial and reputational risks. Chemours securities-fraud class action

About Chemours

The Chemours Company (NYSE: CC) is a global chemical company that develops, manufactures and distributes specialty chemical products used in a range of industrial and consumer applications. Its portfolio serves markets including coatings, plastics, automotive, refrigeration and air conditioning, electronics, telecommunications, energy, healthcare and general manufacturing.

Chemours operates through three primary business segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials.